trial

Treating Nicotine Dependence in Schizophrenic Individuals: Effectiveness of Bupropion - 1

NCTId NCT00124683
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 59 (actual)
Sponsored by National Institute on Drug Abuse (NIDA)
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
59 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2001-09
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
BupropionNicotine transdermal patch

Sponsors

National Institute on Drug Abuse (NIDA)Lead Sponsor

Investigators

1
Tony P George, M.D.Principal Investigator

Sites

0 total

Facts & assertions

3 sourced
Enrollment
59
Phase
PHASE2
Status
COMPLETED
relationships
The graph out of here
drug
Bupropion
drug
Nicotine transdermal patch
drug
lead_sponsor
National Institute on Drug Abuse (NIDA)
company
indication
Tobacco Use Disorder
indication
Tobacco Use Cessation
indication
Schizophrenia
indication
investigator
Tony P George, M.D.
person